Literature DB >> 23398943

The MYB oncogene can suppress apoptosis in acute myeloid leukemia cells by transcriptional repression of DRAK2 expression.

Ping Ye1, Liang Zhao, Thomas J Gonda.   

Abstract

RNA interference-mediated suppression of MYB expression promoted apoptosis in the AML cell line U937, without affecting expression of the anti-apoptotic MYB target BCL2. This was accompanied by up-regulation of the pro-apoptotic gene DRAK2 and stimulation of caspase-9 activity. Moreover, RNA interference-mediated suppression of DRAK2 in U937 cells alleviated apoptosis induced by MYB down-regulation. Finally ChIP assays showed that in U937 cells MYB binds to a conserved element upstream of the DRAK2 transcription start site. Together, these findings identify a novel mechanism by which MYB suppresses apoptosis in an AML model cell line.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23398943     DOI： 10.1016/j.leukres.2013.01.012

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  10 in total

1.  Drak2 is not required for tumor surveillance and suppression.

Authors:  Benjamin A Edwards; Tarsha L Harris; Helen Floersh; John R Lukens; Md Hasan Zaki; Peter Vogel; Thirumala-Devi Kanneganti; Jack D Bui; Maureen A McGargill
Journal:  Int Immunol       Date:  2015-01-07       Impact factor: 4.823

2.  c-Myb Binding Sites in Haematopoietic Chromatin Landscapes.

Authors:  Mads Bengtsen; Kjetil Klepper; Sveinung Gundersen; Ignacio Cuervo; Finn Drabløs; Eivind Hovig; Geir Kjetil Sandve; Odd Stokke Gabrielsen; Ragnhild Eskeland
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

3.  Drak2 Does Not Regulate TGF-β Signaling in T Cells.

Authors:  Tarsha L Harris; Maureen A McGargill
Journal:  PLoS One       Date:  2015-05-07       Impact factor: 3.240

4.  Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells.

Authors:  Kelly Airiau; Valérie Prouzet-Mauléon; Benoit Rousseau; Arnaud Pigneux; Marie Jeanneteau; Manon Giraudon; Kaoutar Allou; Pierre Dubus; Francis Belloc; François-Xavier Mahon
Journal:  Oncotarget       Date:  2016-01-05

5.  STK17B promotes carcinogenesis and metastasis via AKT/GSK-3β/Snail signaling in hepatocellular carcinoma.

Authors:  Yaliang Lan; Jihua Han; Yan Wang; Jiabei Wang; Guangchao Yang; Keyu Li; Ruipeng Song; Tongsen Zheng; Yingjian Liang; Shangha Pan; Xirui Liu; Mingxi Zhu; Yao Liu; Fanzheng Meng; Manzoor Mohsin; Yifeng Cui; Bo Zhang; Sharma Subash; Lianxin Liu
Journal:  Cell Death Dis       Date:  2018-02-14       Impact factor: 8.469

6.  STK17B promotes the progression of ovarian cancer.

Authors:  Liping Jiang; Jinhua Zhou; Shaojie Zhao; Xuzhen Wang; Youguo Chen
Journal:  Ann Transl Med       Date:  2021-03

7.  Prognostic and immune-related value of STK17B in skin cutaneous melanoma.

Authors:  Xueying Shi; Qi Zhou; Bingqian Huang; Shilin Xia; Yuankuan Jiang; Shifeng Fang; Jingrong Lin
Journal:  PLoS One       Date:  2022-02-16       Impact factor: 3.240

8.  Controlled variable selection in Weibull mixture cure models for high-dimensional data.

Authors:  Han Fu; Deedra Nicolet; Krzysztof Mrózek; Richard M Stone; Ann-Kathrin Eisfeld; John C Byrd; Kellie J Archer
Journal:  Stat Med       Date:  2022-07-06       Impact factor: 2.497

9.  DAP Kinase-Related Apoptosis-Inducing Protein Kinase 2 (DRAK2) Is a Key Regulator and Molecular Marker in Chronic Lymphocytic Leukemia.

Authors:  Katarzyna Szoltysek; Carmela Ciardullo; Peixun Zhou; Anna Walaszczyk; Elaine Willmore; Vikki Rand; Scott Marshall; Andy Hall; Christine J Harrison; Jeyanthy Eswaran; Meera Soundararajan
Journal:  Int J Mol Sci       Date:  2020-10-16       Impact factor: 5.923

10.  EGR1 dysregulation defines an inflammatory and leukemic program in cell trajectory of human-aged hematopoietic stem cells (HSC).

Authors:  Christophe Desterke; Annelise Bennaceur-Griscelli; Ali G Turhan
Journal:  Stem Cell Res Ther       Date:  2021-07-22       Impact factor: 6.832
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.